APG-1252

Small molecule

Ascentage Pharma Group Inc.

APG-1252 is one of 119 small molecule programs targeting Lymphoma. It is currently in development.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

MyelofibrosisActive, not recruiting

Small Cell Lung CancerActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

MyelofibrosisPhase 1/Phase 2

Active, not recruiting

Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Terminated· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1/2·NCT04210037·28 enrolled

Advanced Solid Tumors1 trial

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Terminated· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1·NCT03387332·24 enrolled

Other Solid Tumors1 trial

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

Completed· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1·NCT03080311·50 enrolled

Myelofibrosis1 trial

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Withdrawn· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1/2·NCT04354727

Lymphoma1 trial

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1/2·NCT05186012·51 enrolled

1 more indication

Osimertinib1 trial

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Active, not recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1·NCT04001777·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for APG-1252. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APG-1252 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APG-1252. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascentage Pharma Group Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Ascentage Pharma Group Inc.

APG-1252

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Advanced Solid Tumors1 trial

Other Solid Tumors1 trial

Myelofibrosis1 trial

Lymphoma1 trial

Osimertinib1 trial

References

Drug Info

Quick Facts

Related News